Stock Analysis, Dividends, Split History

JOE / St. Joe Co. (THE) financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price17.75
Volume416,800.00
Market Cap ($M)1,079.15
Enterprise Value ($M)945.26
Book Value ($M)533.69
Book Value / Share8.63
Price / Book2.03
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 65,333,311
Common Stock Shares Outstanding 65,897,866
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.09
Return on Assets (ROA)0.06
Return on Equity (ROE)0.09
Balance Sheet (mrq) ($M)
Assets883.77
Liabilities334.23
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues98,796,000.00
Timber Revenue5,622,000.00
Resortsand Leisure Revenues54,820,000.00
Operating Income2.33
Net Income59.24
Earnings Per Share Basic And Diluted0.84
Cash Flow Statement (mra) ($M)
Cash From Operations55.77
Cash from Investing44.45
Cash from Financing44.45
Identifiers and Descriptors
CUSIP790148100
Central Index Key (CIK)745308
Related CUSIPS
790148900 790148950

Split History

Stock splits are used by St. Joe Co. (THE) to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

St. Joe Is A Long-Term Value Investor's Dream

2018-06-13 seekingalpha
The company recently held its annual meeting of shareholders, where it gave an in-depth presentation to shareholders. (2-0)

Top Analyst Reports for Merck, Occidental Petroleum & Capital One Financial

2018-06-07 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Occidental Petroleum (OXY) and Capital One Financial (COF). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (161-0)

Tracking Bruce Berkowitz's Fairholme Portfolio - Q1 2018 Update

2018-05-29 seekingalpha
The portfolio is very concentrated, with St. Joe Companies, Sears Holdings, and its spinoff Seritage Growth Properties forming almost 90% of the entire portfolio. (79-3)

Draining The Swamp: How The St. Joe Company Has Evolved Into The Ultimate Real Estate Moat

2018-05-18 seekingalpha
Began purchasing shares of St. Joe (JOE) in mid-2017 as it became clear the Company was finally in position to fully capitalize on the inherent value of its assets. (9-0)

Top Hamilton medical chief to lead Toronto’s University Health Network

2018-03-12 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (2-0)

Silicon Investor Message Boards

This table lists all message boards related to JOE / St. Joe Co. (THE) on message board site Silicon Investor.

Joe Copiau0027s daytrades/investments and thoughts Joe Copiau0027s daytrades/investments and thoughts Joe Copiau0027s daytrades/investments and thoughts JOE: St. Joe Company JOE: St. Joe Company JOE: St. Joe Company
St. Joe Company (JOE) St. Joe Company (JOE) St. Joe Company (JOE) Joe Stocks Trader Talk Joe Stocks Trader Talk Joe Stocks Trader Talk
Tokyo Joeu0027s Cafe / Societe Anonyme/No Pennies Tokyo Joeu0027s Cafe / Societe Anonyme/No Pennies Tokyo Joeu0027s Cafe / Societe Anonyme/No Pennies Cheap imitation of Joe Copia ......ELXC Cheap imitation of Joe Copia ......ELXC Cheap imitation of Joe Copia ......ELXC
Joeu0027s Tech Assist Joeu0027s Tech Assist Joeu0027s Tech Assist Tokyo Joeu0027s Cafe / Anything goes Tokyo Joeu0027s Cafe / Anything goes Tokyo Joeu0027s Cafe / Anything goes
Fibonacci - Joe DiNapoli Fibonacci - Joe DiNapoli Fibonacci - Joe DiNapoli Ben Cartwright, Adam, Hoss u0026 Little Joe!! Ben Cartwright, Adam, Hoss u0026 Little Joe!! Ben Cartwright, Adam, Hoss u0026 Little Joe!!
CUSIP: 790148100